Annual EBIT
-$99.95 M
+$104.97 M+51.22%
December 31, 2023
Summary
- As of February 7, 2025, FOLD annual earnings before interest & taxes is -$99.95 million, with the most recent change of +$104.97 million (+51.22%) on December 31, 2023.
- During the last 3 years, FOLD annual EBIT has risen by +$151.88 million (+60.31%).
- FOLD annual EBIT is now -1489.31% below its all-time high of -$6.29 million, reached on December 31, 2009.
Performance
FOLD EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
$19.48 M
+$6.86 M+54.33%
September 30, 2024
Summary
- As of February 7, 2025, FOLD quarterly earnings before interest & taxes is $19.48 million, with the most recent change of +$6.86 million (+54.33%) on September 30, 2024.
- Over the past year, FOLD quarterly EBIT has increased by +$31.20 million (+266.20%).
- FOLD quarterly EBIT is now -41.12% below its all-time high of $33.08 million, reached on December 31, 2009.
Performance
FOLD Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$17.88 M
+$31.20 M+63.56%
September 30, 2024
Summary
- As of February 7, 2025, FOLD TTM earnings before interest & taxes is -$17.88 million, with the most recent change of +$31.20 million (+63.56%) on September 30, 2024.
- Over the past year, FOLD TTM EBIT has increased by +$122.22 million (+87.24%).
- FOLD TTM EBIT is now -287.16% below its all-time high of -$4.62 million, reached on June 30, 2010.
Performance
FOLD TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
FOLD EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +51.2% | +266.2% | +87.2% |
| 3 y3 years | +60.3% | +266.2% | +87.2% |
| 5 y5 years | +69.4% | +266.2% | +87.2% |
FOLD EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +52.2% | at high | +126.6% | at high | +92.6% |
| 5 y | 5-year | at high | +70.3% | at high | +122.6% | at high | +94.7% |
| alltime | all time | -1489.3% | +76.9% | -41.1% | +107.2% | -287.2% | +96.0% |
Amicus Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $19.48 M(+54.3%) | -$17.88 M(-63.6%) |
| Jun 2024 | - | $12.62 M(-140.5%) | -$49.08 M(-45.3%) |
| Mar 2024 | - | -$31.15 M(+65.4%) | -$89.72 M(-10.2%) |
| Dec 2023 | -$99.95 M(-51.2%) | -$18.83 M(+60.7%) | -$99.95 M(-28.7%) |
| Sep 2023 | - | -$11.72 M(-58.2%) | -$140.10 M(-5.4%) |
| Jun 2023 | - | -$28.02 M(-32.3%) | -$148.03 M(-14.4%) |
| Mar 2023 | - | -$41.38 M(-29.9%) | -$172.99 M(-15.6%) |
| Dec 2022 | -$204.92 M(-2.0%) | -$58.98 M(+200.3%) | -$204.92 M(-6.0%) |
| Sep 2022 | - | -$19.64 M(-62.9%) | -$218.07 M(-9.4%) |
| Jun 2022 | - | -$52.99 M(-27.7%) | -$240.74 M(+6.4%) |
| Mar 2022 | - | -$73.30 M(+1.6%) | -$226.30 M(+8.2%) |
| Dec 2021 | -$209.08 M(-17.0%) | -$72.13 M(+70.5%) | -$209.08 M(+3.4%) |
| Sep 2021 | - | -$42.31 M(+9.8%) | -$202.27 M(-6.6%) |
| Jun 2021 | - | -$38.55 M(-31.3%) | -$216.46 M(-3.0%) |
| Mar 2021 | - | -$56.09 M(-14.1%) | -$223.06 M(-11.4%) |
| Dec 2020 | -$251.83 M(-25.3%) | -$65.32 M(+15.6%) | -$251.83 M(-7.6%) |
| Sep 2020 | - | -$56.50 M(+25.1%) | -$272.63 M(-0.6%) |
| Jun 2020 | - | -$45.15 M(-46.8%) | -$274.16 M(-11.0%) |
| Mar 2020 | - | -$84.86 M(-1.5%) | -$308.22 M(-8.6%) |
| Dec 2019 | -$337.04 M(+3.2%) | -$86.12 M(+48.4%) | -$337.04 M(+5.5%) |
| Sep 2019 | - | -$58.03 M(-26.7%) | -$319.35 M(-23.2%) |
| Jun 2019 | - | -$79.21 M(-30.3%) | -$415.82 M(+5.7%) |
| Mar 2019 | - | -$113.68 M(+66.1%) | -$393.54 M(+20.5%) |
| Dec 2018 | -$326.69 M(-24.4%) | -$68.43 M(-55.7%) | -$326.69 M(+1.0%) |
| Sep 2018 | - | -$154.50 M(+171.4%) | -$323.58 M(-26.6%) |
| Jun 2018 | - | -$56.93 M(+21.6%) | -$441.08 M(+3.0%) |
| Mar 2018 | - | -$46.82 M(-28.3%) | -$428.06 M(-0.9%) |
| Dec 2017 | -$431.88 M(+117.7%) | -$65.33 M(-76.0%) | -$431.88 M(+1.3%) |
| Sep 2017 | - | -$272.00 M(+519.5%) | -$426.35 M(+113.4%) |
| Jun 2017 | - | -$43.91 M(-13.3%) | -$199.74 M(-3.2%) |
| Mar 2017 | - | -$50.65 M(-15.3%) | -$206.28 M(+4.0%) |
| Dec 2016 | -$198.38 M(+52.0%) | -$59.80 M(+31.7%) | -$198.38 M(+9.8%) |
| Sep 2016 | - | -$45.39 M(-10.0%) | -$180.63 M(+4.4%) |
| Jun 2016 | - | -$50.45 M(+18.0%) | -$173.02 M(+15.8%) |
| Mar 2016 | - | -$42.75 M(+1.7%) | -$149.37 M(+14.4%) |
| Dec 2015 | -$130.54 M(+90.4%) | -$42.05 M(+11.3%) | -$130.54 M(+18.2%) |
| Sep 2015 | - | -$37.78 M(+41.0%) | -$110.45 M(+23.5%) |
| Jun 2015 | - | -$26.80 M(+12.0%) | -$89.44 M(+16.3%) |
| Mar 2015 | - | -$23.92 M(+8.9%) | -$76.88 M(+12.1%) |
| Dec 2014 | -$68.56 M | -$21.95 M(+30.9%) | -$68.56 M(+10.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2014 | - | -$16.77 M(+17.8%) | -$62.33 M(+3.6%) |
| Jun 2014 | - | -$14.24 M(-8.6%) | -$60.14 M(-1.8%) |
| Mar 2014 | - | -$15.59 M(-0.9%) | -$61.24 M(-2.9%) |
| Dec 2013 | -$63.10 M(+21.5%) | -$15.73 M(+7.9%) | -$63.10 M(+4.1%) |
| Sep 2013 | - | -$14.58 M(-4.9%) | -$60.62 M(-2.7%) |
| Jun 2013 | - | -$15.34 M(-12.1%) | -$62.31 M(+10.7%) |
| Mar 2013 | - | -$17.45 M(+31.7%) | -$56.30 M(+8.4%) |
| Dec 2012 | -$51.94 M(+8.5%) | -$13.25 M(-18.6%) | -$51.94 M(+1.9%) |
| Sep 2012 | - | -$16.27 M(+74.4%) | -$50.96 M(+14.7%) |
| Jun 2012 | - | -$9.33 M(-28.8%) | -$44.41 M(-6.9%) |
| Mar 2012 | - | -$13.09 M(+6.8%) | -$47.69 M(-0.4%) |
| Dec 2011 | -$47.89 M(-14.2%) | -$12.26 M(+26.1%) | -$47.89 M(-7.5%) |
| Sep 2011 | - | -$9.73 M(-22.8%) | -$51.80 M(-9.7%) |
| Jun 2011 | - | -$12.60 M(-5.3%) | -$57.36 M(+2.4%) |
| Mar 2011 | - | -$13.30 M(-17.7%) | -$56.02 M(+0.4%) |
| Dec 2010 | -$55.81 M(+787.5%) | -$16.17 M(+5.7%) | -$55.81 M(+750.2%) |
| Sep 2010 | - | -$15.29 M(+35.8%) | -$6.57 M(+42.1%) |
| Jun 2010 | - | -$11.26 M(-14.0%) | -$4.62 M(-33.5%) |
| Mar 2010 | - | -$13.09 M(-139.6%) | -$6.94 M(+10.3%) |
| Dec 2009 | -$6.29 M(-83.9%) | $33.08 M(-347.9%) | -$6.29 M(-87.3%) |
| Sep 2009 | - | -$13.35 M(-1.7%) | -$49.43 M(+8.9%) |
| Jun 2009 | - | -$13.58 M(+9.2%) | -$45.38 M(+7.3%) |
| Mar 2009 | - | -$12.44 M(+23.7%) | -$42.29 M(+8.1%) |
| Dec 2008 | -$39.14 M(-14.6%) | -$10.06 M(+8.2%) | -$39.14 M(-8.0%) |
| Sep 2008 | - | -$9.30 M(-11.4%) | -$42.56 M(-5.6%) |
| Jun 2008 | - | -$10.49 M(+13.0%) | -$45.07 M(+0.5%) |
| Mar 2008 | - | -$9.29 M(-31.1%) | -$44.86 M(-2.1%) |
| Dec 2007 | -$45.80 M(-2.2%) | -$13.48 M(+14.2%) | -$45.80 M(+4.3%) |
| Sep 2007 | - | -$11.81 M(+14.8%) | -$43.91 M(+0.5%) |
| Jun 2007 | - | -$10.28 M(+0.5%) | -$43.69 M(-2.9%) |
| Mar 2007 | - | -$10.23 M(-11.7%) | -$44.99 M(-2.9%) |
| Dec 2006 | -$46.86 M(+124.9%) | -$11.59 M(+0.0%) | -$46.34 M(+16.6%) |
| Sep 2006 | - | -$11.59 M(0.0%) | -$39.75 M(+19.9%) |
| Jun 2006 | - | -$11.59 M(0.0%) | -$33.16 M(+24.8%) |
| Mar 2006 | - | -$11.59 M(+132.0%) | -$26.57 M(+33.0%) |
| Dec 2005 | -$20.83 M(+136.5%) | -$4.99 M(0.0%) | -$19.97 M(+33.3%) |
| Sep 2005 | - | -$4.99 M(0.0%) | -$14.98 M(+50.0%) |
| Jun 2005 | - | -$4.99 M(0.0%) | -$9.99 M(+100.0%) |
| Mar 2005 | - | -$4.99 M | -$4.99 M |
| Dec 2004 | -$8.81 M(+33.4%) | - | - |
| Dec 2003 | -$6.60 M | - | - |
FAQ
- What is Amicus Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Amicus Therapeutics?
- What is Amicus Therapeutics annual EBIT year-on-year change?
- What is Amicus Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Amicus Therapeutics?
- What is Amicus Therapeutics quarterly EBIT year-on-year change?
- What is Amicus Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Amicus Therapeutics?
- What is Amicus Therapeutics TTM EBIT year-on-year change?
What is Amicus Therapeutics annual earnings before interest & taxes?
The current annual EBIT of FOLD is -$99.95 M
What is the all time high annual EBIT for Amicus Therapeutics?
Amicus Therapeutics all-time high annual earnings before interest & taxes is -$6.29 M
What is Amicus Therapeutics annual EBIT year-on-year change?
Over the past year, FOLD annual earnings before interest & taxes has changed by +$104.97 M (+51.22%)
What is Amicus Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of FOLD is $19.48 M
What is the all time high quarterly EBIT for Amicus Therapeutics?
Amicus Therapeutics all-time high quarterly earnings before interest & taxes is $33.08 M
What is Amicus Therapeutics quarterly EBIT year-on-year change?
Over the past year, FOLD quarterly earnings before interest & taxes has changed by +$31.20 M (+266.20%)
What is Amicus Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of FOLD is -$17.88 M
What is the all time high TTM EBIT for Amicus Therapeutics?
Amicus Therapeutics all-time high TTM earnings before interest & taxes is -$4.62 M
What is Amicus Therapeutics TTM EBIT year-on-year change?
Over the past year, FOLD TTM earnings before interest & taxes has changed by +$122.22 M (+87.24%)